Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01312844 · ClinicalTrials.gov registry record · Phase 2
A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01312844: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01312844 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01312844, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the ability of scopolamine to improve the antidepressant effects of ECT and to determine whether scopolamine will shorten the time to response and remission for patients receiving ECT. The hypothesis are: 1. Patients receiving ECT plus scopolamine will have greater improvement in depression symptoms than those receiving ECT plus placebo. 2. Patients receiving scopolamine in addition to ECT will require fewer ECT treatments to obtain response/remission compared to the group receiving ECT plus placebo. 3. Time to response and to remission in the scopolamine group will be significantly shorter compared to ECT alone.
Interventions
- DRUG Scopolamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01312844
The ClinicalTrials.gov registry entry for NCT01312844 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Scopolamine is the first listed.
NCT01312844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01312844 about?
NCT01312844 is a clinical study titled "A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)". The primary purpose of this study is to assess the ability of scopolamine to improve the antidepressant effects of ECT and to determine whether scopolamine will shorten the time to response and remission for patients receiving ECT. The hypothesis are: 1. Patients receiving ECT plus scopolamine wil...
What is the current status of trial NCT01312844?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2010-04. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01312844?
The interventions under investigation include: Scopolamine (DRUG).
Who is sponsoring clinical trial NCT01312844?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.